COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

GISMO - Geographical Information Support for Healthy Mobility (GISMO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03098719
Recruitment Status : Completed
First Posted : April 4, 2017
Last Update Posted : March 4, 2020
University of Salzburg
Information provided by (Responsible Party):
Prof. Josef Niebauer M.D., Ph.D., MBA, Paracelsus Medical University

Brief Summary:
GISMO combines spatial information with findings on the health effects of sustainable, active forms of mobility in the work environment in order to derive evidence-based decision-making bases for a health-promoting, operational mobility management. Existing approaches - with regard to spatial information systems, decision-support systems and health effects of active mobility - are considered and supplemented by our developments and investigations. Achieved non-personal results are provided through standardized web interfaces, ensuring integration into existing and prospective tools of an innovative and health-promoting mobility management.

Condition or disease Intervention/treatment Phase
Health Behavior Behavioral: Active Mobility Not Applicable

Detailed Description:

The World Health Organization recommends a minimum of 150 minutes per week of moderate activity as a minimum for a healthy daily routine. The average employee in Austria works on 5 days a week and covers the distance from his place of residence to his place of work twice. This distance can be actively traveled (e.g., bicycle) or passively (e.g., car).

Due to a moderate physical activity (intensity 4-6 METs, corresponding to 4-6 times resting energy conversion) of 15 minutes in one direction, only the active minimum requirement for everyday activity would be achieved by active mobility to and from the workplace.


2: 1 randomized controlled trial (intervention group: control group)


Motivation of the employees by health care professionals of a sample company (Salzburger Landeskrankenanstalten AG, SALK) to use the public transport as well as the bicycle or footpath on the way from and to the workplace.

Intervention A: Change from car to bicycle for at least 50% of the routes, n = 20-25 Employees who have previously traveled exclusively by car and are living within a radius of ≤10 kilometers from the workplace are motivated by the GVPs to switch to a bicycle. In the case of appropriate proximity, employees can travel the entire path without motorized mobility. The greatest health benefit is to be expected by largely dispensing with motorized mobility at work. In the case of bad weather, cold or similar obstacles, a public transport or car can be used occasionally and exceptionally.

Intervention B: Exit from public transport one or more stations earlier or enter one or more station later, n = 20-25 By extending the path to and from a stop, which is to be actively pursued, a health effect is expected. In the context of this intervention, the availability of time tickets will provide incentives for switching from car to public transport. In addition, the employees are motivated to use the next stop in order to extend the active distance. Access routes can also be covered on foot.

Control group: Maintaining the mobility as before n = 20-25


Before and after the intervention phase of 1 year (to take into account seasonal effects or fluctuations), parameters relevant to health are collected. Finally, the results of the initial examination are compared with those of the final examination in order to examine the effects of healthy mobility on the workplace on cardiovascular risk profile, everyday activity, physical performance, quality of life, mobility behavior, body composition.

The aim of this project is to generate data on the health effects of a healthy mobility.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: GISMO - Geographical Information Support for Healthy Mobility
Actual Study Start Date : March 20, 2017
Actual Primary Completion Date : June 30, 2018
Actual Study Completion Date : October 30, 2019

Arm Intervention/treatment
Experimental: Intervention Behavioral: Active Mobility
see detailed discription

No Intervention: Control

Primary Outcome Measures :
  1. Cardiorespiratory Fitness, i.e. metaboloic equivalents (METs) [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Cardiovascular Risk [ Time Frame: 1 year ]
    Heart Score of the European Society of Cardiology

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • employees of SALK (possibly also employees of other companies), age 18-70 voluntary participation in the study, consent in German language, desire to change the currently prevailing passive mobility behavior.

Exclusion Criteria:

  • physical or psychological condition that makes the participation and completion of the study unlikely. i.e.:

    • Participation in further clinical trials at the same time, or at least four weeks time
    • Pregnancy or lactation
    • Well-known diseases of the movement apparatus, which could influence healthy mobility
    • Subjects with known endogenous or reactive depression or other psychiatric disorders such as panic disorder, schizophrenia, organic mental disorder, delirious, psychotic, phobic, or other psychiatric disorder in the last five years prior to study inclusion
    • Subjects with osteoporosis requiring treatment
    • Severe general disease (e.g., neoplasia, tuberculosis, heart failure)
    • Subjects with chronic infections
    • subjects with alcohol or drug abuse or dependency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03098719

Layout table for location information
Department of Sports Medicine, Prevention and Rehabilitation Paracelsus Medical University
Salzburg, Austria, 5020
Sponsors and Collaborators
Paracelsus Medical University
University of Salzburg
Layout table for additonal information
Responsible Party: Prof. Josef Niebauer M.D., Ph.D., MBA, Professor of Medicine, Paracelsus Medical University Identifier: NCT03098719    
Other Study ID Numbers: GISMO-1
First Posted: April 4, 2017    Key Record Dates
Last Update Posted: March 4, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No